CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 21 - 30 of 826
Study Number Lead Group Study Title CIRB Study Status
A231701CD Alliance Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention Cancer Prevention and Control CIRB Available to Open
A071801 Alliance Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease Adult CIRB - Late Phase Emphasis Available to Open
EA1183 ECOG-ACRIN FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE Adult CIRB - Late Phase Emphasis Available to Open
AOST1521 COG A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate; CDX-011 (Glembatumumab Vedotin; CR011-vcMMAE; IND# 128248; NSC# 763737); in Recurrent or Refractory Osteosarcoma Pediatric CIRB Available to Open
EA8153 ECOG-ACRIN Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial Adult CIRB - Late Phase Emphasis Available to Open
ARET0332 COG A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study Pediatric CIRB Available to Open
EA9152 ECOG-ACRIN A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Adult CIRB - Late Phase Emphasis Available to Open
S1318 SWOG A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone; Vincristine; Methotrexate; 6-Mercaptopurine) for Patients >= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517); Prednisone and Blinatumomab for Patients >= 65 Years Of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL; and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF) Adult CIRB - Early Phase Emphasis Available to Open
A221602 Alliance Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial Cancer Prevention and Control CIRB Available to Open
GOG-0252 GOG A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912) Adult CIRB - Late Phase Emphasis Available to Open
Displaying 21 - 30 of 826